- Home
- BLCO vs RYTM Comparison
BLCO vs RYTM Comparison
Compare BLCO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLCO
- RYTM
- Stock Information
- Founded
- BLCO 1853
- RYTM 2008
- Country
- BLCO Canada
- RYTM United States
- Employees
- BLCO N/A
- RYTM N/A
- Industry
- BLCO Ophthalmic Goods
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- BLCO Health Care
- RYTM Health Care
- Exchange
- BLCO Nasdaq
- RYTM Nasdaq
- Market Cap
- BLCO 4.4B
- RYTM 4.3B
- IPO Year
- BLCO 2022
- RYTM 2017
- Fundamental
- Price
- BLCO $11.70
- RYTM $61.99
- Analyst Decision
- BLCO Hold
- RYTM Strong Buy
- Analyst Count
- BLCO 13
- RYTM 12
- Target Price
- BLCO $15.63
- RYTM $76.75
- AVG Volume (30 Days)
- BLCO 578.9K
- RYTM 525.0K
- Earning Date
- BLCO 07-30-2025
- RYTM 08-05-2025
- Dividend Yield
- BLCO N/A
- RYTM N/A
- EPS Growth
- BLCO N/A
- RYTM N/A
- EPS
- BLCO N/A
- RYTM N/A
- Revenue
- BLCO $4,829,000,000.00
- RYTM $136,863,000.00
- Revenue This Year
- BLCO $6.97
- RYTM $37.56
- Revenue Next Year
- BLCO $5.48
- RYTM $74.99
- P/E Ratio
- BLCO N/A
- RYTM N/A
- Revenue Growth
- BLCO 11.94
- RYTM 48.88
- 52 Week Low
- BLCO $10.45
- RYTM $39.46
- 52 Week High
- BLCO $21.69
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- BLCO 45.65
- RYTM 47.67
- Support Level
- BLCO $11.44
- RYTM $60.70
- Resistance Level
- BLCO $12.70
- RYTM $62.65
- Average True Range (ATR)
- BLCO 0.36
- RYTM 2.39
- MACD
- BLCO 0.01
- RYTM -0.52
- Stochastic Oscillator
- BLCO 30.07
- RYTM 14.04
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.